Arrowhead Pharmaceuticals Inc (ARWR) - Total Liabilities
Based on the latest financial reports, Arrowhead Pharmaceuticals Inc (ARWR) has total liabilities worth $881.88 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Arrowhead Pharmaceuticals Inc (ARWR) cash flow conversion to assess how effectively this company generates cash.
Arrowhead Pharmaceuticals Inc - Total Liabilities Trend (1997–2025)
This chart illustrates how Arrowhead Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of Arrowhead Pharmaceuticals Inc to evaluate the company's liquid asset resilience ratio.
Arrowhead Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Arrowhead Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Addtech AB (publ.)
ST:ADDT-B
|
Sweden | Skr10.80 Billion |
|
Universal Health Services Inc
NYSE:UHS
|
USA | $8.05 Billion |
|
China Avionics Systems Co Ltd
SHG:600372
|
China | CN¥41.16 Billion |
|
Medibank Private Ltd
AU:MPL
|
Australia | AU$1.92 Billion |
|
Doosan
KO:000150
|
Korea | ₩20.11 Trillion |
|
CITIC Securities Company Limited
F:CI9
|
Germany | €1.76 Trillion |
|
LG Innotek Co Ltd
KO:011070
|
Korea | ₩6.26 Trillion |
|
Taiwan Union Technology
TWO:6274
|
Taiwan | NT$21.13 Billion |
Liability Composition Analysis (1997–2025)
This chart breaks down Arrowhead Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ARWR market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.86 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.89 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.64 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Arrowhead Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Arrowhead Pharmaceuticals Inc (1997–2025)
The table below shows the annual total liabilities of Arrowhead Pharmaceuticals Inc from 1997 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-09-30 | $947.02 Million | -0.18% |
| 2024-09-30 | $948.74 Million | +98.32% |
| 2023-09-30 | $478.39 Million | +74.85% |
| 2022-09-30 | $273.60 Million | -9.20% |
| 2021-09-30 | $301.33 Million | +396.22% |
| 2020-09-30 | $60.72 Million | -42.61% |
| 2019-09-30 | $105.81 Million | +546.40% |
| 2018-09-30 | $16.37 Million | -29.31% |
| 2017-09-30 | $23.16 Million | -30.16% |
| 2016-09-30 | $33.15 Million | +46.39% |
| 2015-09-30 | $22.65 Million | +34.55% |
| 2014-09-30 | $16.83 Million | +45.16% |
| 2013-09-30 | $11.59 Million | +50.21% |
| 2012-09-30 | $7.72 Million | +132.19% |
| 2011-09-30 | $3.32 Million | -22.26% |
| 2010-09-30 | $4.28 Million | +50.35% |
| 2009-09-30 | $2.84 Million | -42.57% |
| 2008-09-30 | $4.95 Million | +45.83% |
| 2007-09-30 | $3.40 Million | +16.30% |
| 2006-09-30 | $2.92 Million | +185.16% |
| 2005-09-30 | $1.02 Million | +48.48% |
| 2004-09-30 | $689.70K | +617.11% |
| 2003-09-30 | $96.18K | -94.04% |
| 2002-09-30 | $1.61 Million | +19.50% |
| 2001-09-30 | $1.35 Million | +13.10% |
| 2000-09-30 | $1.19 Million | +10.75% |
| 1999-09-30 | $1.08 Million | -60.24% |
| 1998-09-30 | $2.71 Million | +1.07% |
| 1997-09-30 | $2.68 Million | -- |
About Arrowhead Pharmaceuticals Inc
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, a… Read more